Background Mutations in SOD1 cause 13% of familial amyotrophic lateral sclerosis. In the SOD1 Gly93Ala rat model of amyotrophic lateral sclerosis, the antisense oligonucleotide ISIS 333611 delivered to CSF decreased SOD1 mRNA and protein concentrations in spinal cord tissue and prolonged survival. We aimed to assess the safety, tolerability, and pharmacokinetics of ISIS 333611 after intrathecal administration in patients with SOD1-related familial amyotrophic lateral sclerosis.
Introduction
Our knowledge of the genetic basis of many neurodegenerative diseases has progressed greatly in the past 20 years. Causative mutations have been identifi ed for Huntington's disease, spinal muscular atrophy, spinal and bulbar muscular atrophy, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The challenge now is to turn this knowledge into eff ective treatments. For dominantly inherited disorders in which a mutant protein becomes toxic, reducing the concentration of the protein is a potential approach and antisense oligonucleotides are one means of doing so. 2 Antisense oligonucleotides are short, synthetic nucleic acids that have been chemically modifi ed to increase their stability in biological fl uids and their potency in binding their mRNA target. One mechanism by which antisense oligonucleotides function is by binding to a specifi c target mRNA through Watson-Crick base-pairing and causing degradation of the mRNA by activation of the nuclear enzyme RNase H. 3 Because antisense oligonucleotides do not cross the blood-brain barrier, 4 they must be delivered directly to the CNS to treat neurodegenerative diseases. One possible approach is to administer them intrathecally into the CSF, which results in widespread delivery to the CNS. [4] [5] [6] Genetic changes in more than ten genes are known to cause familial amyotrophic lateral sclerosis, an adultonset neurodegenerative disease characterised by loss or dysfunction of both upper and lower motor neuron pathways 7 and in some cases dementia. Mutations in SOD1 account for roughly 2% of all cases of amyotrophic lateral sclerosis. Although such mutations were identifi ed almost 20 years ago, no treatments exist that substantially slow either the sporadic or SOD1-linked forms of amyotrophic lateral sclerosis. Diff erent SOD1 mutations are associated with diff erent ages of onset and rates of progression, and nearly all are inherited dominantly. 8 The toxicity of SOD1 is the result of a gain of toxic function rather than a loss of enzymatic function; thus, reducing concentrations of the mutant protein is predicted to slow progression of SOD1-linked amyotrophic lateral sclerosis. 7 Evidence of the usefulness of antisense oligonucleotides for treatment of neurodegenerative diseases includes: (1) widespread distribution of antisense oligonucleotides throughout the CNS after CSF administration; [4] [5] [6] (2) reduction of SOD1 mRNA and protein in the brain and spinal cord tissues; 4 and (3) increased survival after direct delivery to the CSF in an SOD1 Gly93Ala animal model of amyotrophic lateral sclerosis. 4 The drug used in these studies was ISIS 333611, an antisense oligonucleotide that reduces expression of wild-type and mutant human SOD1 protein in transgenic rats and in cultured human cells. 4, 9 We aimed to assess the safety, tolerability, and pharmacokinetics of a single dose of ISIS 333611 in patients with SOD1 familial amyotrophic lateral sclerosis. This is the fi rst clinical study to test the eff ects of delivering an antisense oligonucleotide directly into human CSF as a treatment for a widespread disorder of the CNS.
Methods

Study design and participants
We did this placebo-controlled, double-blind, randomised, dose escalation phase 1 study at four centres in the USA (Washington University in St Louis, St Louis, MO; Massachusetts General Hospital, Boston, MA; Johns Hopkins University, Baltimore, MD; and Methodist Neurological Institute, Houston, TX). Patients were eligible if they were aged 18 years or older, had a documented mutation in SOD1, showed clinical signs of weakness attributed to amyotrophic lateral sclerosis, had a forced vital capacity of more than 50% of their predicted value, were not using invasive respiratory support, and were medically able to undergo insertion of a temporary intrathecal catheter. We used a 50% cutoff for forced vital capacity because patients with amyotrophic lateral sclerosis who have a forced vital capacity of more than 50% have fewer complications with minor procedures. 10 Participants who were taking riluzole had to have been on a stable dose for at least 30 days before the start of the study and had to stay on that dose throughout the study. Patients were ineligible if they had been treated with an investigational drug for amyotrophic lateral sclerosis within 30 days or within a period of fi ve-times the half-life of the drug before screening, had clinically signifi cant abnormalities in laboratory test results (including coagulation measures), or had a medical condition that would interfere with the study.
The institutional review boards of the participating study centres approved the study and we did the trial in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All participants provided written informed consent. A data safety and monitoring board monitored the trial.
Randomisation and masking
Participants were enrolled sequentially in four cohorts of escalating single doses of ISIS 333611 (0·15 mg, 0·50 mg, 1·50 mg, 3·00 mg). Within each cohort, patients were randomly assigned to ISIS 333611 or placebo in a ratio of 3:1. An approved protocol amendment made after completion of treatment of the fi rst dose cohort allowed participants to re-enrol in a diff erent cohort if more than 60 days had elapsed since they were treated previously and they still qualifi ed for the study. Re-enrolled patients were re-assigned without regard to previous assignment. After participants were deemed eligible for the study (provided informed consent and met all inclusion criteria), they were sequentially allocated unique patient identifi cation numbers and assigned to a treatment group.
We generated the randomisation sequence with WebEZ, an independent, centralised, web-based randomisation system (Almac Clinical Services, Souderton, PA, USA). We randomly assigned patients in blocks of four sequential participants. Randomisation codes were accessed by the site pharmacist. Study drug or placebo was labelled only with the patient identifi cation number before delivery to the study staff . Patients, caregivers, investigators (including other staff at participating institutions), and Isis Pharmaceuticals personnel were masked to treatment allocation throughout the study. Treatment assignment was known only by the pharmacist at each site, the data safety and monitoring board, and a central biostatistician who provided statistical support to the data safety and monitoring board. No events required premature unmasking of patient allocation or study data.
Procedures
ISIS 333611 (provided in sterile, unpreserved, buff ered saline solution at 20 mg/mL, pH=7·4) and the placebo plus diluents (sterile, phosphate-buff ered saline) were provided by Isis Pharmaceuticals. ISIS 333611 was diluted to the appropriate concentration for each dose and used within 24 h of preparation. The study drug was given as one intrathecal infusion. ISIS 333611 or placebo (0·25 mL) was infused intrathecally for 11 h 22 min with a CADD-MS 3 syringe-based ambulatory infusion pump (Smiths Medical MD, St Paul, MN, USA) equipped with a 3 mL Medication Cartridge via a Codman FlexTip Plus intraspinal catheter. The infusion time was chosen to slowly deliver the exact volume within the programming features of the pump. We chose this volume and timing to provide roughly half a day of dosing, assuming chronic, continuous infusion of 0·5 mL per day in future clinical trials. The tip of the intrathecal catheter was placed under fl uoroscopic guidance near the T8-T10 spinal level by a lumbar puncture using a 17G Tuohy needle inserted into the L3/L4 space, although the protocol allowed placement at a diff erent level if patient anatomy or clinical judgment dictated. We took a CSF sample via the catheter placement needle before infusion to analyse pharmacokinetics and SOD1 protein concentrations. At the end of the infusion, the catheter was immediately removed and another CSF sample taken by a separate lumbar puncture one segment above or below the catheter placement site. We measured ISIS 333611 concentrations in plasma 13 times from before infusion to 12 h after infusion.
Autopsy was not included in the protocol, but through a separate existing protocol we obtained spinal cord tissue samples from a SOD1 Ala4Val patient who was enrolled in cohorts 3 and 4 and who died from amyotrophic lateral sclerosis-related causes 3 months after the study. These samples enabled us to directly assess drug and SOD1 concentrations in this patient. We analysed ISIS 333611 concentration in spinal cord tissue samples taken at autopsy from the cervical, thoracic, and lumbar regions. We measured SOD1 concentration in CSF and spinal cord tissue (100-200 mg samples of frozen cervical and lumbar spinal cord) by a validated, commercially available human SOD1 ELISA (eBioscience BMS222MST). The SOD1 protein concentration is the mean of four independent ELISA assays for CSF and three independent assays for spinal cord tissue. For comparison, we measured SOD1 concentrations in cervical and lumbar spinal cord from autopsy tissue collected at Washington University and Johns Hopkins University (USA) from six patients not included in this trial (three with SOD1 familial amyotrophic lateral sclerosis and three with sporadic amyotrophic lateral sclerosis).
Safety assessments were: recording adverse events, physical and neurological examinations, recording vital signs, clinical laboratory tests (haematology, clinical chemistry, complement, coagulation), electrocardiograms (ECGs), assessment of amyotrophic lateral sclerosis functional rating scale revised score, forced vital capacity, and recording use of concomitant medications. Based on preclinical fi ndings of high exposure to the drug, we monitored for signs of cerebellar dysfunction. Safety assessments were done on day 1 before and after infusion, day 2, day 8, and day 29. Patients were also assessed by a telephone call on day 15. Safety information was reviewed by the data safety and monitoring board after day 8 for the last member of each cohort, to provide a dose escalation recommendation.
We collected data on CSF SOD1 concentration as a pharmacodynamic biomarker in all participants, including after re-enrolment. We estimated ISIS 333611 concentrations by a modifi cation of the hybridisation ELISA method. 11 The method was validated for human plasma and CSF in accordance with current standard practice for immunobinding assays by PPD Bioanalytical (Wilmington, NC, USA). Stability of ISIS 333611 in a frozen matrix (up to 3 months) and up to fi ve freeze-thaw cycles was also confi rmed.
Our primary objective was to assess the safety and tolerability of ISIS 333611 given as a single intrathecal infusion in patients with SOD1 familial amyotrophic lateral sclerosis. Secondary objectives were to assess CSF and plasma pharmacokinetics after intrathecal delivery. 
Statistical analysis
We estimated a sample size of six patients treated with study drug and two treated with placebo per cohort on the basis of previous phase 1 single-dose studies of antisense oligonucleotides to ensure that the safety and tolerability of ISIS 333611 would be adequately assessed while minimising unnecessary patient exposure. We did not do a statistical test of the number of patients needed.
We predicted CSF concentrations of ISIS 333611 on the basis of CSF volume scaling and CSF drug concentrations measured in preclinical studies of Rhesus monkeys.
We did not do a statistical test to compare predicted and measured CSF concentrations of ISIS 333611.
All patients who received treatment were included in the safety, tolerability, and pharmacokinetic assessments. All data summaries and pharmacokinetic analyses were done with Phoenix WinNonlin (version 6.2). This study was registered with Clinicaltrials. gov, number NCT01041222.
Role of the funding source
The sponsors were involved in the design of the study, data collection, data analysis, data interpretation, and writing of the report. All authors had full access to the trial data and are responsible for the accuracy of the data and interpretation of the results. The corresponding author had fi nal responsibility for the decision to submit for publication.
Results
We enrolled 22 participants between March, 2010, and December, 2011, 21 of whom received treatment (fi gure 1). Seven patients enrolled twice, and two patients enrolled three times. All treated participants completed the study. Participants had various SOD1 mutations (the most common was SOD1 Ala4Val) with associated variability in age at disease onset and time since diagnosis (table 1) . Demographic and disease characteristics were much the same between groups, except for the proportion of men (table 2) . 27 patients (84%) reported adverse events (table 3) . The most common adverse events were post-lumbar puncture syndrome and back pain, which in all cases were judged to be related to the infusion procedure and not to the study drug. No adverse events were deemed related to treatment. The most common adverse events did not diff er between ISIS 333611 and placebo groups, and the number of adverse events did not increase with increasing dose of ISIS 333611. Two serious adverse events (lacunar infarction and pneumonia, both requiring admission to hospital) were reported, both in the same placebo-treated patient. In the participants that received ISIS 333611 in more than one cohort, the number of adverse events decreased with re-enrolment (table 4) .
We recorded no changes related to study drug for vital signs, neurological or physical examinations, haematological assessments, clinical chemistry, coagulation measures, complement, urinalysis, or ECGs (data not shown). All participants had a slight, not clinically signifi cant decrease in haematological test results on day 2 that recovered by day 29, probably caused by mild haemodilution secondary to increased hydration in an attempt to prevent post-lumbar puncture syndromes (data not shown). Consistent with reports 12, 13 of nystagmus in some patients with amyotrophic lateral sclerosis, fi ve participants (two in the placebo group and three in the ISIS 333611 group) had nystagmus or abnormal eye movements during the study. One of the participants treated with ISIS 333611 had these signs before treatment. Generally, these abnormalities were intermittent, only evident on neurological examination, not clinically signifi cant, and not clearly related to treatment with ISIS 333611 or lumbar puncture. The amyotrophic lateral sclerosis functional rating scale revised score and forced vital capacity were generally stable during the study and did not diff er substantially between placebo and ISIS 333611 groups (median amyotrophic lateral sclerosis functional rating scale revised score absolute change -1·5 vs -0·6; median forced vital capacity absolute change -3·0% vs -4·8%). After treatment, we detected ISIS 333611 in CSF of all participants in the ISIS 333611 group. CSF concentrations of ISIS 333611 increased with increasing doses (fi gure 2A). The measured con centrations were within two to three times of the predicted concentrations. Although antisense oligonucleotides do not cross the blood-brain barrier when administered systemically, they are cleared from CSF into the plasma consistent with CSF turnover after intrathecal delivery. 4 In cohorts 1 and 2, plasma drug concentrations were generally below the lower limit of quantifi cation of the assay (1 ng/mL). In cohorts 3 and 4, plasma drug concentrations increased during infusion and then rapidly decreased over the next 12 h (fi gure 2B). Table 5 and the appendix show ISIS 3336111 concentrations in plasma (area under the curve 0-24 ) compared with predicted concentrations.
Placebo group (n=8) ISIS 333611 group (n=24)
We analysed spinal cord tissue samples obtained at autopsy from a patient with a SOD1 Ala4Val mutation. ISIS 333611 concentrations were 218 ng/g in a lumbar spinal cord sample, 122 ng/g in a thoracic spinal cord sample, and 39 ng/g in a cervical spinal cord sample. These results and the gradient between lumbar and cervical samples are consistent with expected tissue concentrations based on preclinical studies of Rhesus monkeys (predicted concentration vs measured concentration: 344 ng/g vs 218 ng/g in the lumbar sample, 282 ng/g vs 122 ng/g in the thoracic sample, 36 ng/g vs 39 in the cervival sample; appendix). The CSF concentration of ISIS 333611 at the end of infusion for this patient was 3·5 μg/mL during cohort 3 and 6·3 μg/mL during cohort 4.
We measured SOD1 protein concentrations in cervical and lumbar spinal cord samples from one trial participant and six patients who did not take part in the trial. In the non-trial patients, SOD1 protein concentration ranged from 2141 ng/mL to 4543 ng/mL in the cervical cord and from 1494 ng/mL to 3478 ng/mL in the lumbar cord. For the treated patient, SOD1 concentration was 2259 ng/mL in the cervical sample and 1867 ng/mL in the lumbar sample. The cervical:lumbar ratio of SOD1 concentrations was 1·2:1 in the trial participant and ranged from 0·9:1 to 1·7:1 in patients not treated in the study. In our analysis of CSF SOD1 concentrations in all participants, as expected, 9 CSF SOD1 concentration did not change substantially in participants enrolled in more than one cohort, with most SOD1 CSF concentrations within 12% of the pretreatment or previous cohort value (fi gure 3). 
Discussion
The ability to directly modulate gene expression in the brain and spinal cord aff ords new treatment opportunities for neurological diseases, especially neurodegenerative disorders. Our fi rst-in-human clinical study shows the feasibility of intrathecal delivery of antisense oligonucleotides into the CNS. Because this approach is new, we used single, escalating, low-dose infusions. ISIS 333611 was well tolerated with no dose-limiting toxic eff ects or safety concerns. The data from this study provide encouragement for further development of antisense oligonucleotides for the treatment of neurodegenerative diseases, although the small numbers of participants and low doses limit broader conclusions about the tolerability of intrathecal antisense oligonucleotides. Direct infusion of an antisense oligonucleotide into tumour tissue by convectionenhanced delivery also seems to be similarly well tolerated. 14 We report a clear dose-dependent relation between drug concentrations in CSF and plasma. The agreement between measured pharmacokinetic data and the predicted values supports the use of CSF volume and bodyweight scaling for prediction of human CSF concentration and plasma exposure. These fi ndings should help the selection of doses in future clinical studies.
Based on an estimated tissue half-life of roughly 28 days in preclinical studies, the autopsy samples from a patient who died from amyotrophic lateral sclerosis were taken roughly three half-lives from when the last dose was given. Drug concentrations in spinal cord tissue were easily measured and were much higher than the limit of quantifi cation (5 ng/g). Our results suggest that the human elimination half-life might be in the same range as that in monkeys (roughly 30 days).
In patients who participated in more than one cohort and therefore for whom repeat CSF samples were available, SOD1 CSF concentrations were on average within 12% of the original value. This fi nding is consistent with the low dose of antisense oligonucleotides used and is also consistent with previous repeated measurements of SOD1 CSF concentration, 9 showing an average 7% variation in SOD1 CSF protein concentration when measured 1-12 months apart. The stability of CSF SOD1 concentrations shown by these data, coupled with data from studies of rats, 9 showing that reduction of SOD1 concentrations in brain tissue correlates with reduced SOD1 in the CSF, strongly support use of CSF SOD1 protein concentrations as a pharmacodynamic marker for antisense oligonucleotide activity in future clinical trials of SOD1 amyotrophic lateral sclerosis.
Our study has several limitations. The doses we used were intended to represent a single dose that would be given as a continuous infusion and thus were low. We predict that the highest dose in our study would need to be given continuously for 4 days to reduce SOD1 mRNA and protein concentrations in human spinal cord. The small number of participants also limits conclusions about safety because very rare events might not occur in a small sample. Lastly, the ISIS 333611 group had more men than did the placebo group. Nevertheless, our study is an important fi rst step in using antisense oligonucleotides to treat neurological disease (panel). Patients with Ala4Val mutations in SOD1 typically progress from symptom onset to death very rapidly (ie, in less than 12 months) and thus even short-term reduction of SOD1 concentrations might be benefi cial. Before testing long-term treatment in more slowly progressive SOD1-related amyotrophic lateral sclerosis or treating patients before they develop symptoms, we should more fully understand the eff ects of chronic, long-term reductions of SOD1 concentrations, because knockout of SOD1 has been linked to liver cancer 15 and late life motor neuropathy. 16 Our approach mitigates these concerns because of the only partial reduction of SOD1 concentration and little exposure to peripheral tissues after intrathecal delivery. The antisense oligonucleotide we used is designed to activate RNase H mediated degradation of all SOD1, rather than a particular SOD1 mutant, which enables this approach to be applied broadly to almost all of the more than 100 diff erent mutations in SOD1 known to cause amyotrophic lateral sclerosis. 7 Experiments in mice show that wild-type SOD1 can increase the toxicity of mutant SOD1; 17 thus decreasing both mutant and wildtype SOD1 has an additional theoretical benefi t.
Studies suggest that SOD1 could also be involved in sporadic amyotrophic lateral sclerosis. First, Gruzman and colleagues 18 reported an SOD1-reactive protein (after chemical crosslinking of homogenates of spinal cord tissues) in a small number of patients with sporadic amyotrophic lateral sclerosis but not controls. Second, antibodies that target misfolded SOD1 showed misfolded SOD1 in vulnerable spinal cord neurons of some patients with amyotrophic lateral sclerosis, but not control patients 19, 20 while other well designed, larger studies 21 did not fi nd this pathology in sporadic amyotrophic lateral sclerosis. Third, reduction of SOD1 concentrations in astrocytes derived from patients with sporadic amyotrophic lateral sclerosis reversed the toxic eff ects of these astrocytes when cocultured with motor neurons, 22 again implying that SOD1 might contribute to the pathogenesis of sporadic amyotrophic lateral sclerosis. Although the rationale for treatment with antisense oligonucleotides is strongest for familial SOD1-related amyotrophic lateral sclerosis, this therapeutic approach could be considered for treatment of sporadic amyotrophic lateral sclerosis, should suffi cient data emerge. Our study will enable future studies of similar antisense drugs for familial SOD1 amyotrophic lateral sclerosis, other genetic forms of amyotrophic lateral sclerosis, and other neurodegenerative diseases.
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